Craft

Taibang Biologic Group

Total Funding

$9.6 M

Revenue

$503.7 M

FY, 2019

Taibang Biologic Group Summary

Company Summary

Overview
Taibang Biologic Group (泰邦生物集团有限公司) is a company that focuses on the development, production, and sales of blood products and biopharmaceuticals. Its services include manufacturing human blood albumin, immunoglobulins, coagulation factors, and other related products, as well as medical devices like artificial dura mater and nerve guides.
Type
Private
Status
Active
Founded
2002
HQ
Beijing, CN | view all locations
Website
http://en.chinabiologic.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • David Li

    David Li, Chairman

    • Pang Guangli

      Pang Guangli, Interim CEO

      • Yuan Feng

        Yuan Feng, Senior Vice President

        • Gary Wang

          Gary Wang, General Manager Plasma Resource Center

          LocationsView all

          4 locations detected

          • Beijing, Bei Jing Shi HQ

            China

            No.9-5, Jiangtai West Road, ChaoYang District

          • Beijing Shi

            China

            1-19 Chaoyang Park Rd, Chaoyang Qu

          • Guiyang Shi, Guizhou Sheng

            China

            156 Daqian Rd, Huaxi Qu

          • Taian Shi, Shandong Sheng

            China

            Long Quan Nan Lu, Daiyue Qu

          Taibang Biologic Group Financials

          Summary Financials

          Revenue (Q3, 2020)
          $138.5M
          Gross profit (Q3, 2020)
          $99.3M
          Net income (Q3, 2020)
          $46.4M
          Cash (Q3, 2020)
          $566.9M
          EBIT (Q3, 2020)
          $55.7M

          Footer menu